Publications by authors named "C Busti"
Background: this study aims to evaluate the efficacy of tixagevimab/cilgavimab (Evusheld™) against various SARS-CoV-2 variants, including newer Omicron sublineages, in an immunocompromised cohort and in vitro.
Study Design: Conducted in Italy, this research involves immunocompromised patients who received Evusheld. It evaluates serum neutralization activity against different SARS-CoV-2 strains (20A.
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
J Clin Virol
November 2023
Article Synopsis
- - Tixagevimab-cilgavimab is approved for immunocompromised patients as a preventive treatment, even amid the spread of the Omicron variant (specifically BA.5) and serves as support or an alternative to vaccination.
- - The study measured neutralizing antibody levels in fully vaccinated immunocompromised patients following treatment, finding that only 12.5% achieved adequate antibody levels against BA.5, while most had lower responses compared to another variant.
- - The results indicate that tixagevimab-cilgavimab should not replace vaccination but may be beneficial as a supplementary treatment if the dosage is increased.
Background: This study aims to investigate the activity of the remdesivir-nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this combination.
Methods: A Vero E6 cell-based infection assay was used to investigate the in vitro activity of the remdesivir-nirmatrelvir combination. The SARS-CoV-2 strains tested were 20A.
After almost three years of the pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still spreading around the world, causing notable sanitary and social issues. New antiviral therapies are constantly under investigation. However, few options have been approved for the treatment of COVID-19.
View Article and Find Full Text PDF